Acumen Pharmaceuticals, Inc. (ABOS) Income Statement
ABOS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsABOS revenue and net income
ABOS profit margins
ABOS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ABOS quarterly EPS vs estimates
Acumen Pharmaceuticals beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.43).
ABOS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.4M | $1.4M | $1.7M |
| Cost of revenue | $184,000 | $178,000 | $42.3M | $169,000 | $12.3M | $8.0M | $8.6M |
| Gross profit | −$184,000 | −$178,000 | −$42.3M | −$169,000 | −$12.3M | −$6.6M | −$6.9M |
| Research & development | $104.9M | $93.8M | $42.3M | $32.4M | $12.3M | $8.0M | $8.6M |
| Sales, general & admin | $18.9M | $20.2M | $19.0M | $12.9M | $7.3M | $1.4M | $926,000 |
| Total operating expenses | $123.8M | $114.0M | $61.1M | $45.2M | $7.3M | $1.4M | $926,000 |
| Operating income | −$123.8M | −$114.0M | −$61.1M | −$45.2M | −$19.6M | −$7.9M | −$7.8M |
| Interest income | $7.4M | $14.3M | $8.2M | $2.4M | $84,000 | $1,000 | $45,000 |
| Interest expense | $4.2M | $4.1M | $581,000 | $2.4M | $81.0M | $0 | $0 |
| Income before taxes | −$121.3M | −$102.3M | −$52.4M | −$42.9M | −$100.6M | −$7.3M | −$7.9M |
| Income taxes | — | — | — | −$2.4M | $81.1M | −$1,000 | −$45,000 |
| Net income | −$121.3M | −$102.3M | −$52.4M | −$42.9M | −$100.6M | −$7.3M | −$7.9M |
| EBITDA | −$116.9M | −$98.1M | −$51.6M | −$42.7M | −$100.6M | −$7.9M | $119,000 |
| EPS (diluted) | −$2.01 | −$1.71 | −$1.08 | −$1.06 | −$9.37 | −$64.40 | −$4.88 |
| Gross margin | — | — | — | — | −856.9% | −456.9% | −405.4% |
| Operating margin | — | — | — | — | −1,363.8% | −551.0% | −459.9% |
| Net margin | — | — | — | — | −7,006.0% | −510.1% | −465.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $178,000 | $0 | $0 | $0 | $290,000 | $0 |
| Cost of revenue | — | $46,000 | $45,000 | — | — | $45,000 | $44,000 | $45,000 | $45,000 | $44,000 | $39,000 | $473,000 |
| Gross profit | — | −$46,000 | −$45,000 | — | — | −$45,000 | −$44,000 | −$45,000 | −$45,000 | −$44,000 | −$39,000 | −$473,000 |
| Research & development | $27.8M | $16.5M | $20.5M | $22.0M | $37.1M | $25.3M | $34.6M | $27.2M | $19.5M | $12.4M | $13.3M | $11.2M |
| Sales, general & admin | $4.7M | $4.7M | $4.7M | $4.5M | $4.6M | $5.1M | $5.0M | $5.0M | $4.9M | $5.3M | $5.2M | $4.9M |
| Total operating expenses | $32.6M | $21.1M | $25.2M | $26.5M | $41.8M | $30.4M | $39.6M | $32.3M | $24.4M | $17.8M | $18.4M | $15.6M |
| Operating income | −$32.6M | −$21.1M | −$25.2M | −$26.5M | −$41.8M | −$30.4M | −$39.6M | −$32.3M | −$24.4M | −$17.8M | −$18.5M | −$16.0M |
| Interest income | $1.1M | $1.1M | $1.3M | $1.6M | $2.0M | $2.5M | $3.0M | $3.5M | $3.8M | $4.0M | $4.0M | $3.1M |
| Interest expense | $1.1M | $1.1M | $1.1M | $1.1M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $581,000 | $0 |
| Income before taxes | −$32.7M | −$20.7M | −$25.1M | −$26.5M | −$41.0M | −$28.8M | −$37.2M | −$29.8M | −$20.5M | −$14.9M | −$16.5M | −$13.0M |
| Income taxes | — | — | — | — | — | — | $44,000 | — | — | −$44,000 | $3.8M | −$40,000 |
| Net income | −$32.7M | −$20.7M | −$25.1M | −$26.5M | −$41.0M | −$28.8M | −$37.2M | −$29.8M | −$20.5M | −$14.9M | −$16.5M | −$13.0M |
| EBITDA | −$31.6M | −$19.6M | −$24.0M | −$25.3M | −$39.9M | −$27.7M | −$36.1M | −$28.7M | −$19.5M | −$13.8M | −$15.9M | −$12.9M |
| EPS (diluted) | −$0.45 | −$0.33 | −$0.41 | −$0.44 | −$0.68 | −$0.48 | −$0.62 | −$0.50 | −$0.34 | −$0.25 | −$0.28 | −$0.24 |
| Gross margin | — | — | — | — | — | — | −24.7% | — | — | — | −13.4% | — |
| Operating margin | — | — | — | — | — | — | −22,245.5% | — | — | — | −6,374.5% | — |
| Net margin | — | — | — | — | — | — | −20,873.0% | — | — | — | −5,688.6% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ABOS's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ABOS financial results
Acumen Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $121.3 million. Diluted earnings per share came to −$2.01.
See the ABOS stock overview for the latest quote and news, or the ABOS chart for price history and technical indicators.
ABOS income statement FAQ
Does Acumen Pharmaceuticals have revenue?
Acumen Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Acumen Pharmaceuticals profitable?
No. Acumen Pharmaceuticals reported a net loss of $121.3 million in fiscal 2025.
How much does Acumen Pharmaceuticals spend on research and development?
Acumen Pharmaceuticals spent $104.9 million on research and development in fiscal 2025.
What are Acumen Pharmaceuticals's earnings per share?
Acumen Pharmaceuticals earned $-2.01 per diluted share in fiscal 2025, compared with $-1.71 a year earlier.
When will Acumen Pharmaceuticals report its next earnings?
Acumen Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens.
When does Acumen Pharmaceuticals's fiscal year end?
Acumen Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.